NCT05480384View on ClinicalTrials.gov

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Esophageal AdenocarcinomaEsophageal CancerHER-2 Protein OverexpressionGastroesophageal-junction Cancer
Interventions
DRUG

Nivolumab

Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)

DRUG

Trastuzumab deruxtecan

Given in combination with Nivolumab.

Trial Locations (2)

10021

NOT_YET_RECRUITING

Weill Cornell Medicine/New York-Presbyterian, New York

02903

RECRUITING

Lifespan Cancer Institute, Providence

Sponsors

Lead Sponsor

Brown University

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Brown University

OTHER